Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6525
    +0.0007 (+0.11%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    107,540.71
    -1,065.33 (-0.98%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6039
    +0.0005 (+0.09%)
     
  • AUD/NZD

    1.0905
    +0.0003 (+0.03%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     

The Zacks Analyst Blog Highlights: Las Vegas Sands, Phillips 66, AstraZeneca, Hilton and AutoZone

The Zacks Analyst Blog Highlights: Amazon, Microsoft, IBM, Facebook and Microsoft

For Immediate Release

Chicago, IL – March 21, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Las Vegas Sands LVS, Phillips 66 PSX, AstraZeneca AZN, Hilton HLT and AutoZone AZO.

Here are highlights from Wednesday’s Analyst Blog:

Top Stock Reports for Las Vegas Sands, Phillips 66 and AstraZeneca

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Las Vegas Sands, Phillips 66 and AstraZeneca. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Las Vegas Sands’ shares have lost -2.7% over the past six months, outperforming the Zacks Gaming industry’s decline of -8%. Increased revenues at casino, rooms and malls drove the company’s top line in the fourth-quarter 2018. It generated solid revenues from Macao operations as well. In the next couple of years, the company is likely to spend $2 billion in Macao.

To strengthen its resort portfolio, Las Vegas Sands is focusing on expanding the Four Seasons Tower Suites Macao, St. Regis Tower Suites Macao and the Londoner Macao. The Zacks analyst thinks planned investment in new capital projects in Macao and higher revenues from The Parisian Macao are also likely to drive growth.

Las Vegas Sands’ consistent focus on a convention-based Integrated Resort business model is an added positive. Nevertheless, high debt and competition are worrisome. Estimates for the current year have witnessed upward revisions in the past 30 days.

Shares of Phillips 66 have outperformed the Zacks Oil Refining and Marketing industry over the past year, gaining +2.8% vs. -6.1%. In terms of size, efficiency and strength, Phillips 66 is a leading player in two of its operational segments – chemicals and midstream.

To capitalize on the recent trend of high demand for midstream assets, the company is planning to allocate most of its 2019 capital budget for midstream operations. The Zacks analyst thinks growing petrochemical demand should support the company’s Chemicals businesses.

Phillips 66 is strongly committed to returning cash to shareholders through both dividend payments and share repurchases. However, Phillips 66 is bearing the brunt of increasing turnaround costs, which is hurting its refining business. Moreover, lower crack spread — the income from converting crude into gasoline and diesel — is denting cash flow at its refining unit.

AstraZeneca’s shares have gained +12.8% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry which has gained +4.3% over the same period. AstraZeneca’s core products like Nexium, Crestor and Seroquel are facing generic competition, which is hurting sales.

The diabetes franchise also faces stiff competition while pricing pressure is hurting sales in the Respiratory franchise. Nonetheless, AstraZeneca returned to product sales growth in the second half of 2018 on the back of its newer drugs and looks confident of seeing sustained growth for several years.

The Zacks analyst thinks AstraZeneca’s newer drugs like Lynparza, Tagrisso and Imfinzi should keep contributing to revenues. Meanwhile, several launches are underway across each of the therapeutic areas - Oncology, CV metabolism and Respiratory. Cost-cutting efforts should drive earnings. AstraZeneca also has a promising late-stage pipeline that includes immuno-oncology candidates.  Imfinzi is a key drug in the pipeline.

Other noteworthy reports we are featuring today include Hilton and AutoZone.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                    

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
AutoZone, Inc. (AZO) : Free Stock Analysis Report
 
Hilton Worldwide Holdings Inc. (HLT) : Free Stock Analysis Report
 
Phillips 66 (PSX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research